Literature DB >> 22806273

Role of pertussis toxin-sensitive G-protein, K+ channels, and voltage-gated Ca2+ channels in the antinociceptive effect of inosine.

Sérgio José Macedo-Junior1, Francisney Pinto Nascimento, Murilo Luiz-Cerutti, Adair Roberto Soares Santos.   

Abstract

Inosine is the first metabolite of adenosine. It exerts an antinociceptive effect by activating the adenosine A(1) and A(2A) receptors. We have previously demonstrated that inosine exhibits antinociceptive properties in acute and chronic mice models of nociception. The aim of this study was to investigate the involvement of pertussis toxin-sensitive G-protein-coupled receptors, as well as K(+) and Ca(2+) channels, in the antinociception promoted by inosine in the formalin test. Mice were pretreated with pertussis toxin (2.5 μg/site, i.t., an inactivator of G(i/0) protein); after 7 days, they received inosine (10 mg/kg, i.p.) or morphine (2.5 mg/kg, s.c., used as positive control) immediately before the formalin test. Another group of animals received tetraethylammonium (TEA) or 4-aminopyridine (4-AP) (1 μg/site, i.t., a non-specific voltage-gated K(+) channel blockers), apamin (50 ng/site, i.t., a small conductance Ca(2+)-activated K(+) channel blocker), charybdotoxin (250 pg/site, i.t., a large-conductance Ca(2+)-activated K(+) channel blocker), glibenclamide (100 μg/site, i.t., an ATP-sensitive K(+) channel blocker) or CaCl(2) (200 nmol/site, i.t.). Afterwards, the mice received inosine (10 mg/kg, i.p.), diclofenac (10 mg/kg, i.p., a positive control), or morphine (2.5 mg/kg, s.c., a positive control) immediately before the formalin test. The antinociceptive effect of inosine was reversed by the pre-administration of pertussis toxin (2.5 μg/site, i.t.), TEA, 4-aminopyridine, charybdotoxin, glibenclamide, and CaCl(2), but not apamin. Further, all K(+) channel blockers and CaCl(2) reversed the antinociception induced by diclofenac and morphine, respectively. Taken together, these data suggest that the antinociceptive effect of inosine is mediated, in part, by pertussis toxin-sensitive G-protein coupled receptors and the subsequent activation of voltage gated K(+) channel, large conductance Ca(2+)-activated and ATP-sensitive K(+) channels or inactivation of voltage-gated Ca(2+) channels. Finally, small conductance Ca(2+)-activated K(+) channels are not involved in the antinociceptive effect of inosine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806273      PMCID: PMC3568425          DOI: 10.1007/s11302-012-9327-2

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  49 in total

1.  International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels.

Authors:  George A Gutman; K George Chandy; John P Adelman; Jayashree Aiyar; Douglas A Bayliss; David E Clapham; Manuel Covarriubias; Gary V Desir; Kiyoshi Furuichi; Barry Ganetzky; Maria L Garcia; Stephan Grissmer; Lily Y Jan; Andreas Karschin; Donghee Kim; Sabina Kuperschmidt; Yoshihisa Kurachi; Michel Lazdunski; Florian Lesage; Henry A Lester; David McKinnon; Colin G Nichols; Ita O'Kelly; Jonathan Robbins; Gail A Robertson; Bernardo Rudy; Michael Sanguinetti; Susumu Seino; Walter Stuehmer; Michael M Tamkun; Carol A Vandenberg; Aguan Wei; Heike Wulff; Randy S Wymore
Journal:  Pharmacol Rev       Date:  2003-12       Impact factor: 25.468

Review 2.  Calcium receptor-mediated intracellular signalling.

Authors:  Donald T Ward
Journal:  Cell Calcium       Date:  2004-03       Impact factor: 6.817

Review 3.  Immunomodulatory and neuroprotective effects of inosine.

Authors:  György Haskó; Michail V Sitkovsky; Csaba Szabó
Journal:  Trends Pharmacol Sci       Date:  2004-03       Impact factor: 14.819

Review 4.  Potassium channels and pain: present realities and future opportunities.

Authors:  María Ocaña; Cruz Miguel Cendán; Enrique José Cobos; José Manuel Entrena; José Manuel Baeyens
Journal:  Eur J Pharmacol       Date:  2004-10-01       Impact factor: 4.432

5.  Positive inotropic response to inosine in the in situ canine heart.

Authors:  C E Jones; J X Thomas; M D Devous; C P Norris; E E Smith
Journal:  Am J Physiol       Date:  1977-10

Review 6.  Pharmacology of adenosine A2A receptors and therapeutic applications.

Authors:  Bertil B Fredholm; Rodrigo A Cunha; Per Svenningsson
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

Review 7.  Adenosine in the spinal cord and periphery: release and regulation of pain.

Authors:  Jana Sawynok; Xue Jun Liu
Journal:  Prog Neurobiol       Date:  2003-04       Impact factor: 11.685

8.  Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo.

Authors:  Gregorio Gomez; Michail V Sitkovsky
Journal:  Blood       Date:  2003-08-28       Impact factor: 22.113

9.  Participation of the L-arginine-nitric oxide-cyclic GMP-ATP-sensitive K+ channel cascade in the antinociceptive effect of rofecoxib.

Authors:  Myrna Déciga-Campos; Francisco J López-Muñoz
Journal:  Eur J Pharmacol       Date:  2004-01-26       Impact factor: 4.432

Review 10.  Role of ion channels in mechanisms controlling gastrointestinal pain pathways.

Authors:  Fernando Cervero; Jennifer M A Laird
Journal:  Curr Opin Pharmacol       Date:  2003-12       Impact factor: 5.547

View more
  8 in total

1.  Adenosine A1 receptor-dependent antinociception induced by inosine in mice: pharmacological, genetic and biochemical aspects.

Authors:  Francisney Pinto Nascimento; Sérgio José Macedo-Júnior; Fabrício Alano Pamplona; Murilo Luiz-Cerutti; Marina Machado Córdova; Leandra Constantino; Carla Inês Tasca; Rafael Cypriano Dutra; João B Calixto; Allison Reid; Jana Sawynok; Adair Roberto Soares Santos
Journal:  Mol Neurobiol       Date:  2014-07-27       Impact factor: 5.590

2.  Glutamatergic system and mTOR-signaling pathway participate in the antidepressant-like effect of inosine in the tail suspension test.

Authors:  Filipe Marques Gonçalves; Vivian Binder Neis; Débora Kurrle Rieger; Tanara V Peres; Mark William Lopes; Isabella A Heinrich; Ana Paula Costa; Ana Lúcia S Rodrigues; Manuella P Kaster; Rodrigo Bainy Leal
Journal:  J Neural Transm (Vienna)       Date:  2017-07-10       Impact factor: 3.575

3.  A1 Adenosine Receptor Activation Inhibits P2X3 Receptor-Mediated ATP Currents in Rat Dorsal Root Ganglion Neurons.

Authors:  Jia-Wei Hao; Wen-Long Qiao; Qing Li; Shuang Wei; Xue-Mei Li; Ting-Ting Liu; Chun-Yu Qiu; Wang-Ping Hu
Journal:  Mol Neurobiol       Date:  2022-09-08       Impact factor: 5.682

4.  Signaling pathways underlying the antidepressant-like effect of inosine in mice.

Authors:  Filipe Marques Gonçalves; Vivian Binder Neis; Débora Kurrle Rieger; Mark William Lopes; Isabella A Heinrich; Ana Paula Costa; Ana Lúcia S Rodrigues; Manuella P Kaster; Rodrigo Bainy Leal
Journal:  Purinergic Signal       Date:  2016-12-13       Impact factor: 3.765

5.  The antidepressant-like effect of inosine in the FST is associated with both adenosine A1 and A 2A receptors.

Authors:  Manuella P Kaster; Josiane Budni; Marta Gazal; Mauricio P Cunha; Adair R S Santos; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2013-04-25       Impact factor: 3.765

6.  The role of peripheral adenosine receptors in glutamate-induced pain nociceptive behavior.

Authors:  S J Macedo-Júnior; F P Nascimento; M Luiz-Cerutti; A R S Santos
Journal:  Purinergic Signal       Date:  2021-04-16       Impact factor: 3.765

7.  Inosine attenuates spontaneous activity in the rat neurogenic bladder through an A2B pathway.

Authors:  Claire Doyle; Vivian Cristofaro; Bryan S Sack; Stefan N Lukianov; Mattias Schäfer; Yeun Goo Chung; Maryrose P Sullivan; Rosalyn M Adam
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

8.  Inosine Improves Neurogenic Detrusor Overactivity following Spinal Cord Injury.

Authors:  Yeun Goo Chung; Abhishek Seth; Claire Doyle; Debra Franck; Daniel Kim; Vivian Cristofaro; Larry I Benowitz; Duong D Tu; Carlos R Estrada; Joshua R Mauney; Maryrose P Sullivan; Rosalyn M Adam
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.